Are socio-economic status indicators barriers for enrollment in phase 1 clinical trials?

R Reema Mody (Hackensack University Medical Center, Hackensack, NJ) E Erica DeCecco (Hackensack University Medical Center, Hackensack, NJ) N Narjust Florez (Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA) V Vanisha Patel (2Hackensack Meridian Health, Hackensack, United States) L Lili Zhang A Andre Goy (14Division of Oncology, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack Meridian Health, Hackensack, NJ) T Tracy Ann Proverbs-Singh (John Theurer Cancer Center, Hackensack, NJ) A Andrew L. Pecora (Outcomes Matter Innovations LLC, Jersey City, NJ) N Nicole Lieber (John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ) A Alison Morawaski (John Theurer Cancer Center, Hackensack, NJ) E Evan Patrick Mckiernan (John Theurer Cancer Center, Hackensack, NJ) N Nicholas Hoffman (John Theurer Cancer Center, Hackensack, NJ) L Lisa Sarmasti (John Theurer Cancer Center, Hackensack, NJ) D Danielle Schillen (Hackensack University Medical Center, Hackensack, NJ) N Nicole Montes (John Theurer Cancer Center, Hackensack, NJ) M Michael Postma (Hackensack University Medical Center, Hackensack, NJ) M Martin Gutierrez (Hackensack University Medical Center, Hackensack, NJ) M Miguel Gonzalez Velez (Hackensack University Medical Center, John Theurer Cancer Center, Hackensack, NJ)

Abstract

1652 Background: Socio-economic Status (SES) indicators create barriers to access Phase 1 clinical trial (Ph1) enrollment, particularly for underrepresented minorities (URM). However, it remains unclear whether they directly affect enrollment after screening, or represent upstream barriers. We evaluated whether SES indicators impacted the enrollment rate in Ph1. Methods: All patients were screened for Ph1 at Hackensack University Medical Center (2014-2025). Patient ZIP codes were linked to the U.S. Census data (ACS 2018-2022) to derive neighborhood-level SES indicators: median household income (MHI), educational attainment (Bachelor), poverty rate (PR), unemployment rate (UR), and median home value (MHV). SES indicators were compared to national and state census benchmarks. The primary outcome was enrollment rate by SES indicators. We performed univariate analyses (Mann-Whitney U tests, chi-square), stratified analyses by race/ethnicity and gender, temporal trend analysis, and multivariable logistic regression. Results: A total of 1,316 patients were screened for 140 Ph1. Demographics were non-Hispanic White (NHW) 66.2%, Hispanic 19.0%, African American/Black (AA) 7.8%, Asian 6.5%. No SES variable predicted enrollment: median income (enrolled $62,646 vs not-enrolled $61,820, p=0.450), education (38.3% vs 37.9%, p=0.598), poverty (12.9% vs 12.3%, p=0.416), unemployment (6.1% vs 6.0%, p=0.422), home value ($277,461 vs $275,697, p=0.605). SES quartile analysis showed no enrollment gradient (Q1=61.7%, Q2=58.1%, Q3=60.5%, Q4=63.8%; p=0.491). Findings were consistent across all racial/ethnic groups (all p>0.05), see Table 1, gender (all p>0.05), age groups <65 and ≥65 years (all p>0.05), and time periods 2014-2019 vs 2020-2025. When compared to their respective racial/ethnic groups U.S. Census averages, it demonstrated atypical SES profiles: Hispanic patients had higher education (36.6% vs 20.6%), AA showed higher SES across all indicators, and Asians showed lower SES, suggesting regional selection bias in who reaches Ph1 screening. Conclusions: When patients reach Ph1 screening, SES indicators do not predict enrollment, demonstrating that equitable enrollment practices can be achieved at screening. Although there were no visible SES-related barriers at the enrollment point, disparities exist among groups likely suggesting referral patterns prior to screening. Future research should examine how to improve access to Ph1 in URM and upstream inequities. SES analysis stratified by race/ethnicity. Race SES Variable p-value NHW MHI 0.4476 NHW Education 0.4585 NHW PR 0.7483 NHW UR 0.6957 NHW MHV 0.4982 Hispanic MHI 0.8270 Hispanic Education 0.4104 Hispanic PR 0.0646 Hispanic UR 0.2401 Hispanic MHV 0.9677 AA MHI 0.9569 AA Education 0.7355 AA PR 0.9112 AA UR 0.3962 AA MHV 0.3076 Asian MHI 0.2037 Asian Education 0.3200 Asian PR 0.2067 Asian UR 0.0867 Asian MHV 0.1677

Article Details

Volume / Issue Vol. 44, Issue 16_suppl
Published June 01, 2026
Pages 1652-1652
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (18)

R

Reema Mody

Hackensack University Medical Center, Hackensack, NJ

E

Erica DeCecco

Hackensack University Medical Center, Hackensack, NJ

N

Narjust Florez

Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

V

Vanisha Patel

2Hackensack Meridian Health, Hackensack, United States

L

Lili Zhang

A

Andre Goy

14Division of Oncology, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack Meridian Health, Hackensack, NJ

T

Tracy Ann Proverbs-Singh

John Theurer Cancer Center, Hackensack, NJ

A

Andrew L. Pecora

Outcomes Matter Innovations LLC, Jersey City, NJ

N

Nicole Lieber

John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ

A

Alison Morawaski

John Theurer Cancer Center, Hackensack, NJ

E

Evan Patrick Mckiernan

John Theurer Cancer Center, Hackensack, NJ

N

Nicholas Hoffman

John Theurer Cancer Center, Hackensack, NJ

L

Lisa Sarmasti

John Theurer Cancer Center, Hackensack, NJ

D

Danielle Schillen

Hackensack University Medical Center, Hackensack, NJ

N

Nicole Montes

John Theurer Cancer Center, Hackensack, NJ

M

Michael Postma

Hackensack University Medical Center, Hackensack, NJ

M

Martin Gutierrez

Hackensack University Medical Center, Hackensack, NJ

M

Miguel Gonzalez Velez

Hackensack University Medical Center, John Theurer Cancer Center, Hackensack, NJ